டேவிட் செபெஸ்டா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டேவிட் செபெஸ்டா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டேவிட் செபெஸ்டா Today - Breaking & Trending Today

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners

Share this article
Share this article
LONGMONT, Colo., April 28, 2021 /PRNewswire/ KromaTiD is pleased to announce that BroadOak Capital Partners has made an investment in the Company. KromaTiD s sales and operations are rapidly accelerating, driven by growing market adoption of their products and services, such as the recently launched dGH In-Site™ and dGH SCREEN™ products for gene editing and gene therapy applications. This capital will be used to accelerate commercialization, support ongoing product development, and to increase capacity to meet growing demand.
KromaTiD s directional Genomic Hybridization™, or dGH™, today provides the genomic structural context necessary to optimize gene editing strategies for research and clinical purposes, such as therapeutic gene editing based on CRISPR technologies, requiring measurements that can only be made with a single cell, genome-wide analysis provided by dGH™. ....

Christopher Tompkins , David Sebesta , Kromatid Inc , Broadoak Capital Partners , Genomic Hybridization , Bill Snider , Health Care Amp Hospitals , Venture Capital , கிறிஸ்டோபர் டாஂப்‌கிந்ஸ் , டேவிட் செபெஸ்டா , ர சி து ஸ்னைடர் , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் , உயிரி தொழில்நுட்பவியல் , துணிகர மூலதனம் ,

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Christopher Tompkins , David Sebesta , Kromatid Inc , Broadoak Capital Partners , Genomic Hybridization , Bill Snider , David Sebesta Phone , கிறிஸ்டோபர் டாஂப்‌கிந்ஸ் , டேவிட் செபெஸ்டா , ர சி து ஸ்னைடர் ,

Applied Spectral Imaging and KromaTiD Announce Strategic Commercial Partnership

Applied Spectral Imaging and KromaTiD Announce Strategic Commercial Partnership
News provided by
Share this article
Share this article
CARLSBAD, Calif. and LONGMONT, Colo., April 6, 2021 /PRNewswire/ Applied Spectral Imaging (ASI) and KromaTiD, Inc. announced today that they have entered into a strategic commercial partnership, granting ASI worldwide rights to market KromaTiD s proprietary Pinpoint FISH™ (PPF) probes and assay services. PPF is used by researchers around the world to directly analyze unique and small genomic targets in tissues, microarrays, and dissociated cells.
KromaTiD, Inc.
KromaTiD currently provides commercial dGH™ and PPF products and services to industry, institutional and academic researchers assessing the integrity of engineered cells, as well as researchers visualizing novel genomic structural variants in oncology and undiagnosed genetic diseases. ....

Bandview Karyotyping , David Sebesta , Limor Shiposh , Kromatid Inc , Applied Spectral Imaging , Chief Executive Officer , Chief Commercial Officer , Spectral Imaging , டேவிட் செபெஸ்டா , பயன்படுத்தப்பட்டது நிறமாலை இமேஜிங் , தலைமை நிர்வாகி அதிகாரி , தலைமை வணிகரீதியானது அதிகாரி , நிறமாலை இமேஜிங் ,

KromaTiD Announces the Addition of James Chomas to the Board of Directors

KromaTiD Announces the Addition of James Chomas to the Board of Directors
News provided by
Share this article
Share this article
LONGMONT, Colo., Feb. 11, 2021 /PRNewswire/ KromaTiD is pleased to announce that Colorado biomedical entrepreneur James Chomas has joined the company s Board of Directors. Jim has a track record of developing innovative healthcare solutions and driving adoption by customers and strategic partners. KromaTiD s sales and operations are rapidly accelerating and Jim s deep experience in healthcare product definition, commercialization, and organizational growth bring vital expertise to KromaTiD s Board.
KromaTiD s directional Genomic Hybridization™ or dGH™ today provides the genomic structural context necessary to understand the potential risks of therapeutic gene editing; critical measurements that can only be made with a single cell, genome-wide analysis such as dGH™. Christopher Tompkins, KromaTiD s CEO and CTO says, We are ....

United States , Prnewswire Kromati , Christopher Tompkins , David Sebesta , James Chomas , Kromatid Inc , Genomic Hybridization , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டோபர் டாஂப்‌கிந்ஸ் , டேவிட் செபெஸ்டா ,